Ribopro focuses on the development and manufacture of mRNA and LNPs. Credit: Volha_R/Shutterstock.

ImmunoPrecise Antibodies (IPA) has entered a strategic partnership with Ribopro to transform therapeutic antibody discovery and development.

The partnership will combine the mRNA [messenger ribonucliec acid]-based antigen expression expertise of Ribopro with the in silico and wet-lab antibody discovery capabilities of IPA.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Utilising Ribopro’s mRNA sequence optimisation and lipid nanoparticle-based delivery expertise alongside IPA’s single-cell analysis, B-cell screening and deep-learning AI-powered discovery workflows, the partnership focuses on expediting and improving the development of therapeutics by antigen presentation improvement and immune responses enhancement.

The use of Ribopro’s mRNA and lipid-based nanoparticle technologies within the collaboration allows for efficient antigen expression, potentially leading to immune responses and strengthening the path to discovering new antibody therapeutics.

IPA’s strategy melds AI-driven analytics with specialised wet-lab methodologies to design and optimise antibodies with clinical relevance.

ImmunoPrecise Antibodies chief scientific officer Dr Ilse Roodink stated: “We are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mRNA immunisation platform in this alliance.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Combining Ribopro’s and IPA’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions.”

Based in the Netherlands and founded in 2020, Ribopro is a technology and service provider focusing on the development and manufacture of mRNA and LNPs.

Through subsidiaries such as BioStrand, ImmunoPrecise Antibodies in Canada and Europe, and Talem Therapeutics, IPA offers a solution for developing antibody therapeutics.

By integrating multi-omics modelling, systems biology and AI, IPA allows for the discovery of fully human therapeutic antibodies for complex disease targets.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now